# Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

> **NCT04830345** · PHASE3 · COMPLETED · sponsor: **EuBiologics Co.,Ltd** · enrollment: 290 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** ATGC-100 100U
- **BIOLOGICAL:** Botox 100U

## Key facts

- **NCT ID:** NCT04830345
- **Lead sponsor:** EuBiologics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-29
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830345, "Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04830345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*